Research Groups and R&D Platforms: Diagnostics
Research Group:
Bio-inspired Engineering
Tan-Phat Huynh
tan.huynh[at]abo.fi
Laboratory of Physical Chemistry,
Åbo Akademi University
Bio-inspired Engineering Group
Atomic-force microscopy, Biomarker, Biomolecular chemistry, Cancer, Chemical Physics, Combinatorial chemistry, Diagnostics, Electron microscopy, Fluorescence spectroscopy, FTIR or RAMAN spectroscopy, Molecular diagnostics, Molecular modelling, Organic Chemistry, Pattern recognition, Physico-chemical properties, Physics, Point of care
Research Group:
Biomaterials for controlled delivery of drugs and antigens and for tissue engineering
Mika Jokinen
mika.jokinen[at]turkuamk.fi
Chemical Engineering / Biomaterials & Diagnostics,
Turku University of Applied Sciences
Uudet materiaalit ja prosessit
Biopharmaceuticals, Biotechnology, Diagnostics, Drug delivery, Fluorescence spectroscopy, Formulation, FTIR or RAMAN spectroscopy, In Vitro Diagnostics, Particle size analysis, Physico-chemical properties, Preclinical development
Research Group:
Bio-Organic Chemistry
Tuomas Lönnberg
tuanlo[at]utu.fi
Department of Chemistry,
University of Turku
Basic research, Biomolecular chemistry, Diagnostics, Fluorescence spectroscopy, Hit to lead, In Vitro Diagnostics, Lead optimization, NMR, Nucleic acids, Organic Chemistry, Organic compounds, Synthetic chemistry
R&D Platform:
Cancer Centre of the Turku University Hospital
The Tyks Cancer Centre guarantees high-quality cancer treatment and research in the hospital districts of Southwest Finland, Satakunta and Vaasa.
The Tyks Cancer Centre works to unify treatment practices and treatment quality, and to see to it that patients get access to treatment according to unified criteria in a timely manner in the western coastal area of Finland. This puts the patients with cancer at the right place at the right time, regardless of where they live.
The Tyks Cancer Centre is a part of the Cancer Center Finland (FICAN) – a national enterprise under construction to coordinate cancer treatment, research and education in the whole of Finland.
Breast cancer, Cancer, Clinical development, Colorectal cancer, Diagnostics, In Vitro Diagnostics, In Vivo Diagnostics, Lung cancer, Melanoma, Ovarian cancer, Prostate cancer, R&D Platforms, Squamous cell carcinoma
R&D Platform:
Turku BioImaging
Turku BioImaging, TBI (www.bioimaging.fi), is an umbrella organization for “all things imaging” in Turku, jointly operated by Åbo Akademi University and the University of Turku. TBI was initiated in 2007 as a broad-based, interdisciplinary imaging consortium that aims at bringing together all biological and medical imaging expertise in Turku and elsewhere in Finland. In 2017, Turku BioImaging is celebrating its journey of 10 years, from a small 2-person unit to a large, fully functioning organization.
Atomic-force microscopy, Basic research, Clinical development, Diagnostics, Electron microscopy, FTIR or RAMAN microscopy, High throughput imaging, Imaging, Imaging software, In Vivo Diagnostics, PET, Preclinical development, R&D Platforms, Super-resolution imaging, Ultrasound imaging
R&D Platform:
Turku Metabolomics Centre
The Turku Metabolomics Centre (TMC) was established in the Fall of 2017, and currently comprises four analytical laboratories on the University of Turku and Åbo Academy campuses, with the primary focus on biomedical and clinical applications. TMC covers a broad range of analytical methods, useful for discovery studies, hypothesis-driven targeted studies as well as clinical applications in Good Laboratory Practice (GLP) setting. The methods include:
1. Targeted quantitative analyses by mass spectrometry (MS) of specific groups of metabolites, e.g. bile acids, endocannabinoids, amino acids, eicosanoids.
2. Global profiling of molecular lipids (lipidomics) and polar metabolites.
3. Diagnostic, drug metabolism and pharmacokinetic applications in Good Laboratory Practice (GLP) setting.
4. Tissue metabolomics by Nuclear Magnetic Resonance (NMR).
5. How dietary intake affects blood metabolism.
TMC infrastructure currently includes 7 MS instruments (2 x UHPLC-QTRAP/QqQ-MS, 2 x UHPLC-QqQ-MS, 1 x GC-QqQ-MS, 2 x GC-QMS) and 2 NMR instruments (1 x 600 MHz and 1 x 400 MHz). The 400 MHz spectrometer is equipped with a high resolution magic angle spinning probe for the detection of metabolites in tissue and cell samples without the need for extensive sample preparation. The 600MHz instrument is equipped with a cooled sample handling robot with space for 300 samples allowing high throughput liquid NMR studies. Two new MS instruments also being purchased this year.
Basic research, Bioinformatics, Diagnostics, In Vitro Diagnostics, Machine learning, Metabolomics, NMR, Pattern recognition, R&D Platforms, Systems Biology, Target discovery
